Highlights of the NCCN Oncology Research ProgramThe NCCN Oncology Research Program (ORP) strives to improve the quality of life for patients and reduce cancer-related deaths by advancing cancer therapies through research. Since the program's establishment in 1999, the NCCN ORP has brought millions of dollars in research grants to investigators at NCCN Member Institutions. Research grants are provided to NCCN through collaborations with pharmaceutical and biotechnology companies; these grants are in turn used to support scientifically meritorious cancer research efforts.NCCN ORP studies typically explore new avenues of clinical investigation and seek answers to important cancer-related questions. All studies are approved and funded through a scientific peer-review process and are overseen by the ORP.Several NCCN-sponsored studies funded through the grant mechanism are highlighted below.Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)Principal Investigator: Marc Chamberlain, MDCondition: Anaplastic glioma; glioblastoma (arm closed)Institution: Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, University of Washington, Seattle, WAThis phase II trial is studying how well bendamustine hydrochloride works in treating patients with recurrent or progressive anaplastic glioma or glioblastoma multiform. (Please note: the glioblastoma arm of this study is closed.)Primary Outcome Measures:
Six month progression-free survival rate
Secondary Outcome Measures:
Best overall response
Contact: Sandra K. Johnston, RN, PhD • 206-288-6365ClinicalTrials.gov Identifier: NCT00823797Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone SarcomasPrincipal Investigator: David Loeb, MD,...